Dimpygal

Quick links to important sections

Dimpygal

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dimpygal

Property Description
Active ingredient Dimpylate (Diazinon)
Form Liquid solution/Concentrate for dip emulsion
Pharmacological class Ectoparasiticide
Common use Control of external parasitic infestations
Origin Synthetic chemical compound

Identity and Classification

Dimpygal is a specific veterinary medicine designated as a topical ectoparasiticide, meaning it is used to manage parasites residing on the exterior of an animal's body. The product’s core activity is provided by the chemical compound Dimpylate, which is also identified by the non-proprietary name Diazinon. Chemically, Dimpylate is categorized as an organophosphorus compound (OP), a family of potent synthetic agents. This specific chemical classification corresponds to its primary application as an external antiparasitic agent.

Composition, Form, and General Action

The formulation of Dimpygal is a single-ingredient product, where Dimpylate serves as the sole active agent, which is synthetic in origin. The medicine is typically supplied as a liquid solution or an emulsifiable concentrate, forms designed for external (topical) administration via dilution and application as a bath or spray. The general purpose of Dimpygal is the effective management of common ectoparasitic infestations, particularly against ticks, mites, and lice on the bodies of specified livestock. Its action stems from Dimpylate's role as an inhibitor of the acetylcholinesterase (AChE) enzyme in the parasite’s nervous system, leading to the rapid, incapacitating overstimulation of nerve transmission and subsequent control of the pest population.

What side effects are possible with Dimpygal?

The official safety profile for Dimpygal (Dimpylate/Diazinon) is documented by regulatory authorities, classifying possible adverse reactions based on their frequency and the body system affected. Since Dimpylate is an organophosphorus compound, the safety documentation addresses risks to both the treated animal and human handlers.

Adverse reactions are grouped by system-organ class. Reactions affecting the Skin and Subcutaneous Tissue Disorders, such as local skin irritation and alopecia (hair loss), have been classified as occasional following application. The most serious safety concern is systemic intoxication, which is listed as a rare adverse reaction. This condition aligns with organophosphorus compound toxicity, potentially involving Nervous System Disorders (e.g., tremor, loss of reflexes) and Respiratory Difficulties.

Population and Safety Constraints

Official regulatory documents define specific exclusions for the use of Dimpygal:

  • Age and Health Status: The product is not for use in very young animals, such as puppies under 12 weeks of age, nor should it be applied to sick or recovering animals.
  • Organ Impairment: Use is contraindicated in animals with known liver disorder.
  • Reproductive Status: The medicine should not be used in pregnant or lactating animals.
  • Handler Restriction: Individuals who are under medical advice not to work with anticholinesterases are prohibited from handling this product, due to the recognized risk of sensitization.

This framework of officially documented adverse events, frequency classifications, and specific limitations defines the medicine’s risk profile, ensuring safety parameters are communicated without crossing into therapeutic or dosing information.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Dimpylate (Diazinon) overexposure is characterized by a cholinergic crisis, which is defined by a specific set of clinical manifestations and requires immediate emergency action.


Overdose Scope

Property Description
Documented overdose presentations Overexposure may result in miosis (pinpoint pupils), excessive salivation, bronchorrhea (increased bronchial secretions), vomiting, diarrhea, headache, muscle twitching (fasciculations), and weakness.
Physiological systems affected (as stated in label) Neurological, respiratory, and cardiovascular systems; leading to potential respiratory failure, coma, or convulsions.
Exposure-related factors (if applicable) Ingestion of certain formulations, particularly those containing a petroleum solvent, may cause chemical pneumonitis. Individuals with baseline reduced cholinesterase enzyme levels are noted to be at higher risk of acute poisoning.
Emergency-response statements Immediate washing of affected skin or flushing of eyes with plenty of water for at least 15 minutes while removing all contaminated clothing is required. DO NOT induce vomiting.

Resulting Overdose Structure

Official overdose statements:

  • Overexposure may rapidly progress to life-threatening outcomes, including respiratory arrest, necessitating urgent care and hospital observation for a minimum of 12 to 48 hours.
  • The documented primary antidote is Atropine, which is administered until the patient is atropinized, with Pralidoxime chloride (2-PAM) noted as an official antidotal adjunct for severe cases.
  • The official management protocols strictly contraindicate the use of medications such as morphine, theophylline, and reserpine due to risk of exacerbating toxic effects.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Dimpygal overdose profile based on the distinct cholinergic crisis symptom cluster, which officially mandates seeking immediate medical attention and calling a poison control center due to the documented risk of life-threatening systemic outcomes like respiratory arrest. The official guidance requires specific procedural steps, such as immediate decontamination and specialized antidotal treatment protocols, while explicitly forbidding actions such as inducing vomiting.

Therapeutic Uses of Dimpygal

What Dimpygal Treats: Main Uses and Benefits

Dimpygal (Dimpylate/Diazinon) is a veterinary medicine that is commonly used exclusively in the field to help manage health issues caused by external parasitic infestations and contribute to improved comfort in livestock. The active substance is used for the control of parasitic conditions caused by sheep scab, blowfly, ticks, keds, and lice on sheep. The medication is used within therapeutic areas involving heightened responses to the following conditions:


It is considered relevant in conditions characterized by periods of heightened symptoms such as scab and mange, which present with symptoms related to physical discomfort. It helps address symptom clusters that include intense pruritus (itching), skin irritation, and the development of lesions.

“This application may assist in easing the overall symptom burden, supporting patients during difficult episodes.”

This treatment is commonly applied in scenarios where there are established infestations causing noticeable discomfort. The medicine is generally relevant for managing Wood conditions that involve episodic or fluctuating manifestations, and is commonly used to help manage risks associated with anticipated episodes like blow-fly strike or re-infestation. The treatment may assist with maintaining functional stability when symptoms become more disruptive during flare-ups.


Quick Fact: Supports easing Dermatological Distress (Symptoms of intense itching, skin irritation, and lesions caused by ectoparasites).

Regulatory References

  1. Veterinary Medicines Directorate Public Assessment Report

Eligibility and Restrictions for Use

Dimpygal (Dimpylate/Diazinon) is a veterinary ectoparasiticide strictly approved for use only in specified livestock (Target Species) that are in generally good health. Regulatory documents establish mandatory exclusions based on species, health status, and life stage.

Status Population/Condition
Contraindicated Humans and Non-Target Species (e.g., Cats, Birds, Fish)
Animals with Known Hypersensitivity to Dimpylate or excipients
Animals with a known Liver Disorder (Hepatic Impairment)
Restricted Use Animals that are Sick or Recovering from illness
Pregnant animals (Use is not recommended by regulators)
Very Young/Immature Animals (Contraindicated below a minimum age threshold)

The official profile establishes use is prohibited for any animal that is currently sick or recovering. Furthermore, use is not permitted in lactating animals producing milk for human consumption. These official statements define the narrow population that can receive the medicine under standard regulatory conditions.

What should I know about interactions with other medicines?

The official interaction profile for Dimpygal (Dimpylate/Diazinon) is defined by strict regulatory constraints related to its chemical classification as an organophosphorus compound. The primary interaction is classified as a significant pharmacodynamic effect, arising from the potential for an additive anticholinesterase effect when combined with similar agents.

Due to this interaction risk, co-administration with other substances in the same pharmacological class is a formally restricted combination. The required constraints for co-use are summarized in regulatory documents:

Interacting Substance/Class Regulatory Restriction Classification Timing Rule
Other Organophosphorus Compounds Categorical prohibition against co-use 14 days separation required
Medicines not compatible with OPs Categorical prohibition Not applicable
Levamisole Requires mandatory separation from administration 14 days separation required
Other Insecticides Avoidance period after product removal 7 days post-removal

The mandated timing rules are a direct consequence of this interaction profile, necessitating clear separation periods for co-administered medicinal products. An interval of at least 14 days must elapse between administering the dip formulation and dosing with products containing Levamisole or an organophosphorus compound. Furthermore, the use of other insecticides is restricted for seven days after the removal of the collar formulation. This structure establishes clear, non-advisory constraints for product combination.

Mechanism of Action

How Dimpygal Works: Mechanism of Action

Enzyme Target and Inhibition

Dimpygal's core mechanism is the inhibition of acetylcholinesterase (AChE), a critical enzyme responsible for breaking down the neurotransmitter acetylcholine (ACh). This interaction is the basis for the resulting physiological effects by preventing the natural termination of nerve signals.


Neurotransmitter Overload and Hyper-Signaling

By blocking AChE, Dimpygal causes ACh to accumulate excessively within the cholinergic synapses of the target organism's nervous system. This sustained accumulation results in a state of continuous, unregulated firing of nerve receptors, leading to widespread and systemic neural overstimulation.


Physiological Consequence: Spastic Paralysis

The relentless hyperactivity and subsequent exhaustion of the neuromuscular junctions drive the target organism into a state of spastic paralysis. This complete loss of motor control and vital function is a direct physiological consequence of the mechanistic action.

Dosage and Administration Information

How Dimpygal is Used: Official Administration Guidelines

Dimpygal (Dimpylate/Diazinon) is administered strictly as a topical ectoparasiticide following established protocols. Its use is governed by rules pertaining to administration route, specific dilution ratios, required contact time, and handling procedures.


Administration Scope and Dosing

The sole authorized method of use is as a plunge dip, which requires the full immersion of the animal in the prepared wash. Application via equipment such as sprayers or jetters is explicitly prohibited.

The process begins with the preparation of the bath: The concentrate is initially diluted with clean water at a ratio of 1 part concentrate to 1500 parts water. To maintain the necessary concentration as the dip volume decreases, a stronger replenishment ratio of 1 part concentrate to 1000 parts water is added, typically after every 20 sheep.


Procedural and Time Constraints

Administration requires the use of a Closed Transfer System for accurate and safe dispensing of the concentrate into the bath. To ensure effective application, the sheep must remain immersed for a minimum of 30 seconds for standard parasite control, or 1 minute when treating conditions like sheep scab. The animal's head must be fully submerged twice during the process for complete coverage.

Time constraints are strict: The final diluted dip wash must be used only on the day of preparation and must be immediately discarded afterward, preventing the use of an unstable solution. Use is restricted to sheep that possess at least three weeks of wool growth following shearing. Rams and fat sheep may require assistance through the bath, and lambs must be dipped separately from ewes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dimpygal

Evidence for Management of External Parasitic Infestations

The research base for Dimpygal (Dimpylate/Diazinon) consists of studies conducted to support its regulation as an ectoparasiticide for livestock. The evidence primarily was studied for the management of several conditions characterized by fluctuating or episodic manifestations, including Sheep Scab, and infestations of Ticks, Keds, Lice, and Blowfly. The research was conducted during periods of increased symptom activity where outcomes related to physical discomfort were assessed.

The original regulatory approval was supported by Pivotal Efficacy Trials, which were often structured as controlled field studies and early Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving sheep with existing natural infestations. The research was evaluated for its association with changes in pest populations. For newer versions of the product, authorization often involves Bioequivalence Studies, which are used to confirm that the generic product is chemically equivalent to the reference product whose research evidence was previously reviewed by regulatory bodies.

Outcomes Measured in Key Studies

The primary focus of the research was the assessment of parasite load measures. These outcomes reflecting daily functioning or activity level were the key metrics used for regulatory review. Studies tracked the number of live parasites—such as mites, ticks, and lice—at various time points after application. The research also monitored clinical signs, examining outcomes related to physical discomfort such as pruritus (itching) and skin lesions caused by the infestations. For prevention claims, such as against Blowfly Strike, the research examined the duration over which the animals were observed to remain free from new infestation.

Research Gaps and Areas of Uncertainty

The body of evidence supporting Dimpylate is associated with a High level of regulatory confidence. This acceptance across regulatory bodies reflects that the data supporting the core claims were evaluated in multiple jurisdictions. However, a key limitation is that many currently authorized products rely on the findings of the original historical pivotal studies. This means that comparative evidence is lacking for every generic formulation in full-scale, contemporary controlled trials, and long-term effects are not fully established concerning the durability of control over consecutive seasons. Continued post-marketing surveillance research is ongoing to monitor the emergence of parasite resistance.

Key Studies & References

  1. Veterinary Medicines Directorate Public Assessment Report (UKPAR 253319) – Assessment of Ectoparasiticide Claims for Sheep

Frequently Asked Questions (FAQ)

Common questions about Dimpygal (FAQ)


Q: How quickly should I expect Dimpygal to start working?

According to official product information, the antiparasitic effect is achieved after a minimum immersion time of 30 seconds to 1 minute in the prepared solution. The onset of action is tied to achieving the required concentration during the contact time specified for administration.


Q: What are the most common mild side effects of taking Dimpygal?

Regulatory documents classify reactions affecting the skin and underlying tissues as occasional adverse reactions. The most commonly noted effects include localized skin irritation and temporary alopecia (hair loss) following the product's application.


Q: Can Dimpygal cause drowsiness or affect driving?

Dimpygal is an organophosphorus compound with recognized risks of systemic effects, which can involve the nervous system in the animal. Official handler warnings advise against use for individuals who are under medical advice not to work with anticholinesterases (the class of chemical Dimpygal belongs to).


Q: Is it normal to feel a little dizzy after starting Dimpygal?

Official warnings related to Dimpygal highlight that handling the product is restricted for individuals who have been advised by a doctor to avoid working with anticholinesterases. This caution is in place due to the recognized risk of adverse effects related to anticholinesterase exposure.


Q: Are there any long-term effects of using Dimpygal?

Studies and regulatory documents note that long-term effects are not fully established, particularly concerning the durability of pest control over consecutive seasons. Regulatory authorization often relies on original historical studies supporting the initial claims.


Q: What should Dimpygal look like (color, shape, pill markings)?

Dimpygal is not a solid pill. It is supplied as a liquid solution or an emulsifiable concentrate, which must be diluted for external use as a plunge dip, according to the official product information.


Q: Does Dimpygal require any special monitoring while taking it?

Administration requires the use of a Closed Transfer System for accurate and safe dispensing of the concentrate. Furthermore, official regulations require that the disposal of all waste products is handled according to specialized hazardous waste procedures.


Q: Is Dimpygal used for pain management?

Dimpygal is authorized for the control of external parasitic infestations. While the studies track outcomes related to the reduction of physical discomfort (like itching), it is not classified by regulators as a primary pain management medication.


Q: What should I do if I accidentally miss a dose of Dimpygal?

Regulatory labels for drug products include procedural advice for action to be taken if an intake is missed. The patient information leaflet provides specific instructions for managing a lapse in the dosing schedule.


Q: What if I take too much Dimpygal by mistake?

The regulatory documents contain a dedicated section defining the signs of overdose (intoxication) and the recommended management for this condition. The official label information should be consulted to understand the necessary immediate steps.


Q: Why are there different strengths of Dimpygal available?

Different product strengths are available due to variations in the concentration of the active ingredient, Dimpylate. These variations may exist between a reference product and a bioequivalent hybrid medicine.


Q: Is there a maximum time I should take Dimpygal?

Official regulatory documents specify the duration of treatment for which the medicine has been studied and authorized for each specific indication. The medicine is authorized for a specific, defined duration of treatment and is not generally intended for continuous use.


Q: Does Dimpygal affect my mood or mental state?

Systemic effects from this class of chemical are a rare but serious adverse reaction that can potentially involve Nervous System Disorders. Mood or mental state changes are not explicitly listed in the veterinary adverse reaction profile.


Q: Can I stop taking Dimpygal suddenly?

Regulatory documents address the need for dose titration or tapering off for certain medicinal products where sudden discontinuation may cause adverse effects. The official product label outlines the administration procedures, including any requirements for dose adjustment upon treatment completion.


Q: What's the difference between the brand name and generic versions of Dimpygal?

The generic version contains the same active substance and is used for the same indications as the reference product. However, it may differ in inactive ingredients, name, appearance, and packaging, according to regulatory guidelines for generic medicines.


Q: Can Dimpygal be used for chronic conditions?

The product is indicated for the management of specific, often episodic parasitic infestations. Official information notes that the long-term effects concerning durable control over consecutive seasons are not fully established.


Q: Does the efficacy of Dimpygal decrease over time?

Regulatory review notes that post-marketing surveillance is ongoing to monitor the emergence of parasite resistance. This is a recognized concern for the long-term effectiveness of the product class.


Q: How long does a typical course of Dimpygal treatment last?

The official label specifies the required duration of treatment for each specific indication. The length of the treatment course is defined by the regulatory authorization.


Q: Will Dimpygal help with my symptoms immediately, or does it take time?

The product is fast-acting, requiring only 30 seconds to 1 minute of contact time for the initial effect to occur. However, the full relief of clinical signs and symptoms may occur over a longer duration.


Q: Is it possible to be allergic to Dimpygal?

Yes, official regulatory documents state that the product is contraindicated in animals with a Known Hypersensitivity to Dimpylate or its inactive components, confirming the possibility of an adverse immune reaction.

How should Dimpygal be stored and disposed of?

How to Store and Dispose of Dimpygal?

The official regulatory labeling requires Dimpygal (Dimpylate/Diazinon) to be stored in its original, tightly closed container at a temperature not exceeding 25°C (77°F). Storage must protect the product from direct light and heat. For safety, the product must be kept out of the sight and reach of children and stored securely away from food or animal feedstuffs.

Stability and Disposal

The shelf-life of the unopened product is defined by the regulatory labeling, but the diluted solution must be used immediately after preparation. Unused or expired Dimpygal and waste materials must be disposed of according to National Waste Disposal regulations. Due to its classification as extremely dangerous to aquatic life, the product must not contaminate ponds, waterways, or ditches, and requires specialized hazardous waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dimpygal found in:

A-Z Index: